No Prescription |
 |
 | ||
|
Verpamil Calan |
|
| ||
No Prescription » Prescription Drugs 17 » Verpamil Calan Verapamil is used with or without other medications to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes heart attacks and kidney problems. Verapamil is called a calcium channel blocker. It works by relaxing blood vessels so blood can flow more easily.Verapamil is also used to prevent chest pain (angina). It may help to increase your ability to exercise and decrease how often you may get angina attacks. Verapamil is also used to control your heart rate if you have a fast/irregular heartbeat (such as atrial fibrillation). It helps to lower the heart rate helping you to feel more comfortable and increase your ability to exercise. Buy Verpamil Calan and other Prescription Drugs 17 products online at Medstore. Buy Online at Medstore - Click Here!
About Verpamil Calan: Product Type: Prescription Drugs 17 Verpamil ( Calan Isoptin Generic Verapamil ) Verpamil (Calan Isoptin Generic Verapamil) Calan Isoptin Generic Verapamil 40mg Calan Isoptin Generic Verapamil Verpamil
View more Prescription Drugs 17 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
